Hair loss due to Mounjaro: causes, what to expect, and when to act

What SURMOUNT-1 actually reported about hair shedding

The most reliable data on hair loss from Mounjaro comes from the SURMOUNT-1 trial, published in the New England Journal of Medicine. In that study, alopecia (the clinical term covering most forms of hair shedding) was recorded in 5.7% of participants on the 15mg dose (roughly one person in seventeen at the highest strength) compared with 1% in the placebo group. That gap is real and statistically meaningful, but several things are worth noting. First, the trial participants lost an average of around 20% of their body weight over 72 weeks. Second, significant weight loss alone, regardless of the method used to achieve it, is a well-documented trigger for telogen effluvium. Third, the trial did not find a causal mechanism linking tirzepatide's dual GIP and GLP-1 receptor activity directly to follicle behaviour.

The NHS notes tirzepatide's most common side effects are gastrointestinal; NHS guidance on tirzepatide lists hair loss as a less common effect, occurring in fewer than one in ten people. That framing is accurate: the majority of people taking Mounjaro do not report shedding that they find clinically significant.

Why weight loss triggers temporary shedding — and what that means for Mounjaro users

Telogen effluvium works on a delay. Hair follicles cycle through growth, rest, and shedding phases; a physiological shock (illness, surgery, crash dieting, or rapid weight reduction) can push a large proportion of follicles into the resting phase simultaneously. The shedding shows up roughly two to three months later, which is why people often notice it well into treatment rather than at the start.

For anyone on tirzepatide, the timeline often coincides with the dose-escalation phase, when weight loss is fastest. That timing can make it look like the dose increase is the problem, when the trigger was actually the weight change that preceded it. Understanding what drives Mounjaro-related hair loss in this way can reduce unnecessary alarm. The good news: telogen effluvium is self-limiting. Once the body adapts to a new, stable weight, follicles return to their normal cycle. Most people see regrowth within three to six months of the shedding peak, without any specific treatment.

Protein intake is a meaningful variable here. On a significantly reduced-calorie diet, it is easy to under-eat protein, and the hair follicle is among the tissues most sensitive to amino acid shortage. A quick check worth building into any week: scan your daily meals for at least one substantial protein source at each main meal, eggs, lean meat, fish, legumes, Greek yoghurt. It takes about a minute and is one of the most practical things someone on a GLP-1 treatment can do for both muscle preservation and scalp health.

Steps that may reduce the impact, and what is unlikely to help

There is no single evidence-based protocol for preventing weight-loss-related shedding entirely, but several strategies are consistently mentioned in clinical guidance on telogen effluvium. Adequate dietary protein (typically 1.2–1.6g per kilogram of body weight is discussed in nutritional literature alongside obesity pharmacotherapy) is considered important for limiting muscle and tissue loss during rapid weight reduction. Iron and ferritin levels are worth checking with your GP if shedding is heavy, since subclinical iron deficiency is common and worsens follicle shedding. Zinc and biotin deficiencies can also contribute, though supplementing either above normal levels is not routinely recommended. You can read about practical approaches to managing Mounjaro hair loss in more detail, but the core principle is nutritional adequacy rather than any specific product.

What is unlikely to help: switching doses speculatively, stopping treatment without medical advice, or adding topical treatments aimed at androgenetic alopecia (genetic hair thinning), a different condition with different causes. The broader relationship between Mounjaro's side effects and hair is worth reading alongside this page if you want the full picture before making any decisions, and if you have also noticed changes in your digestion, our separate page covering whether Mounjaro can give you constipation addresses another side effect that often comes up around the same time.

When to seek medical attention, and how to report

Most shedding related to rapid weight loss is self-limiting and does not require escalation. You should speak to a GP or your prescribing clinician if: the hair loss is patchy or in defined bald spots (which may suggest a different underlying cause such as alopecia areata); if shedding is severe and prolonged beyond six months without any sign of slowing; if you notice significant eyebrow or eyelash involvement; or if the loss is accompanied by fatigue, cold intolerance, or other symptoms that could indicate a thyroid problem.

The MHRA's Yellow Card scheme exists precisely for this kind of reporting. If you believe a medicine is contributing to a side effect (including hair shedding) report it via the Yellow Card service. This is how post-market safety signals are built, and your report counts. Tirzepatide carries a Black Triangle (▼) status in the UK, meaning additional monitoring is active and reports carry particular value.

Our prescribers can discuss what you are experiencing and whether any action is needed. Start a free consultation if you are considering treatment, or contact the team if you are an existing patient with a concern about a current side effect. Aftercare is part of the service, seven days a week.